The kallikrein-kinin system: from mediator of inflammation to modulator of cardioprotection
- PMID: 16259723
- DOI: 10.1163/156856005774382760
The kallikrein-kinin system: from mediator of inflammation to modulator of cardioprotection
Abstract
Kinin is an important mediator of hyperalgesia, inflammatory conditions and asthma. It causes pain, inflammation, increased vascular permeability and vasodilatation. Several kinin antagonists have been developed with the aim of treating these pathologies. Kinin B2 receptor agonists and kallikrein may have clinical utility in the treatment of hypertension, left ventricular hypertrophy, ischemic heart disease, congestive heart failure and diabetes. However, there is a need to know whether there is a safe therapeutic window between potential cardio-protective and pro-inflammatory effects following administration of kinin B2 receptor agonists.
Similar articles
-
Cardiovascular properties of the kallikrein-kinin system.Curr Med Res Opin. 2002;18(1):10-7. doi: 10.1185/03007990212500093. Curr Med Res Opin. 2002. PMID: 11999140 Review.
-
Pharmacologic targets and prototype therapeutics in the kallikrein-kinin system: bradykinin receptor agonists or antagonists.ScientificWorldJournal. 2006 Oct 9;6:1247-61. doi: 10.1100/tsw.2006.226. ScientificWorldJournal. 2006. PMID: 17041716 Free PMC article. Review.
-
Therapeutic prospects for bradykinin receptor agonists in the treatment of cardiovascular diseases.IDrugs. 2004 Oct;7(10):926-34. IDrugs. 2004. PMID: 15478018 Review.
-
The kallikrein-kinin system: current and future pharmacological targets.J Pharmacol Sci. 2005 Sep;99(1):6-38. doi: 10.1254/jphs.srj05001x. J Pharmacol Sci. 2005. PMID: 16177542 Review.
-
The kallikrein/kinin system and kinin antagonists in trauma.Immunopharmacology. 1996 Jun;33(1-3):279-83. doi: 10.1016/0162-3109(96)00071-9. Immunopharmacology. 1996. PMID: 8856162 Review.
Cited by
-
The influence of heart failure self-care on health outcomes: hypothetical cardioprotective mechanisms.J Cardiovasc Nurs. 2009 May-Jun;24(3):179-87; quiz 188-9. doi: 10.1097/JCN.0b013e31819b5419. J Cardiovasc Nurs. 2009. PMID: 19279494 Free PMC article. Review.
-
Increased Reactive Oxygen Species Generation Contributes to the Atherogenic Activity of the B2 Bradykinin Receptor.Front Med (Lausanne). 2019 Feb 21;6:32. doi: 10.3389/fmed.2019.00032. eCollection 2019. Front Med (Lausanne). 2019. PMID: 30847343 Free PMC article.
-
Racial Disparities in Analgesic and Psychiatric Medication Use During End-Of-Life Care in Advanced-Stage Colorectal Cancer: A Retrospective Cohort Study.Cancer Res Commun. 2025 Jul 1;5(7):1095-1101. doi: 10.1158/2767-9764.CRC-25-0164. Cancer Res Commun. 2025. PMID: 40536154 Free PMC article.
-
Enalapril protects against myocardial ischemia/reperfusion injury in a swine model of cardiac arrest and resuscitation.Int J Mol Med. 2016 Nov;38(5):1463-1473. doi: 10.3892/ijmm.2016.2737. Epub 2016 Sep 15. Int J Mol Med. 2016. PMID: 27633002 Free PMC article.
-
Regulatory effects of ferritin on angiogenesis.Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):570-5. doi: 10.1073/pnas.0812010106. Epub 2009 Jan 6. Proc Natl Acad Sci U S A. 2009. PMID: 19126685 Free PMC article.